Clinical trial · no report yet · Phase 3
NCT03975647
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
- NCT03975647 ↗
- Active not recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- 67 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 41 | |
| YouTube | 14 | |
| Podcasts | 11 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- tucatinib; placebo; T-DM1
- Arms
- Tucatinib + T-DM1 · Experimental
- Placebo + T-DM1 · Active comparator
- Enrollment
- 466
- Primary outcomes
- Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Oct 2, 2019
- Primary completion
- Jun 29, 2023
- Results posted
- Yes
- Registry record
- NCT03975647 · updated Jul 23, 2026
Publications
linked from the registry- Hurvitz SA, Loi S, O'Shaughnessy J, Okines AFC, Tolaney SM, Sohn J, Saura C, Zhu X, Cameron D, Bachelot T, Hamilton E, Curigliano G, Wolff AC, Harbeck N, Masuda N, Vahdat L, Zaman K, Valdes-Albini F, Block M, Pluard T, Tan TJ, Gawryletz C, Chan A, Bedard PL, Yerushalmi R, Xu B, Schmitt M, Xie D, Borges VF; HER2CLIMB-02 study investigators. Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02. Ann Oncol. 2026 Mar;37(3):341-352. doi: 10.1016/j.annonc.2025.11.005. Epub 2025 Nov 17. PubMed 41260264